Determinants of Malignant Hypertension Onset and Related Target Organ Damages: the HAMA Biobank
Recruiting
Observational Study
Malignant Hypertension
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 1,000 (estimated)
- Sponsor
- Centre Hospitalier de PAU · Other
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your Eligibility
About This Trial
The HAMA bank is an initiative aimed at collecting, preparing, and storing biological samples from patients treated for malignant hypertension and included in the HAMA cohort. Conducted under CRB (ISO20387) conditions, this biobank serves as an essential resource for understanding the disease's pathophysiology, as well as for identifying novel biomarkers and therapeutic targets
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* patients included in the HAMA cohort with the following critera :
* Malignant hypertension according to the classic definition (Severe hypertension associated with severe hypertensive retinopathy)
* Severe hypertension associated with acute target organ damage due to high…
Contacts